Hot Products

p-Coumaryl alcohol
Catalog No: CFN96011

p-Coumaryl alcohol derivatives have antioxidant activity.

p-Cymene
Catalog No: CFN70239

Reference standards.

PD98059
Catalog No: CFN60018

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Pectolinarigenin
Catalog No: CFN99010

Pectolinarigenin possesses anti-inflammatory, antiallergic and hepatoprotective activities.It is a dual inhibitor of COX-2/5-LOX,and the IC50 >1 microM; it also can increase activity levels of GSH, GR, GCS, and GST, as well as SOD.

Pectolinarin
Catalog No: CFN99727

Pectolinarin has antioxidant, antiobesity, analgesic, and hepatoprotective activity, it may inhibit eicosanoid formation in inflammatory lesions.

Pedalitin
Catalog No: CFN96045

Pedalitin is a mixed-type inhibitor of tyrosinase. In the assay of α-glucosidase inhibition, rosmarinic acid is a competitive inhibitor, whereas both methyl rosmarinate and Pedalitin are mixed-type inhibitors.

Pedatisectine F
Catalog No: CFN98040

Standard reference

Pedunculoside
Catalog No: CFN99701

Pedunculoside shows significant hypocholesterolemic and anti-inflammatory activities, it shows potential nitric oxide inhibitory activities with the IC50 value ranging from 14.92 uM to 52.23 uM.

Peimine
Catalog No: CFN99996

Peimine has good anti-inflammatory effects in vivo, it inhibits the production of inflammatory cytokines induced by LPS through blocking MAPKs and NF-κB signaling pathways. It also has antitussive and sedative actions, the action being suspected to be central in nature.

Peiminine
Catalog No: CFN99997

Peiminine has potent anti-inflammatory, anti-allergic, antitussive, and expectorant effects. It induces autophagic cell death thus represses colorectal carcinoma tumor growth. Peiminine can inhibit lung inflammation and pulmonary fibrosis in a rat model of bleomycin-induced lung injury, by reducing circulating IFN-γ levels and inhibiting signal transduction pathways involving TGF-β, CTGF, ERK1/2, NF-κB and FasL.